StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.92−0.05 (-0.84%)

Close on Nov 17, 2026Market cap $148.00KP/E –Yield –

AgomAb Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -€51.74M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€51.74M–
FY2024Dec 31, 2024-€46.83M–
FY2023Dec 31, 2023-€24.59M–

More AgomAb Therapeutics figures

See a number that looks wrong?